BASL Annual Meeting delegates please remember that you can view all of the session recordings across BASL, BLTG and BLNA for at least 3 months post congress by logging back into the portal using your original log in link. 


September 2022 - Dates to be confirmed

Thank you to everyone that contributed, supported, organised and attended the virtual BASL 2021 Annual Meeting and for making the meeting a great success. The organising committee are planning a face to face meeting for next year and look foward to announcing the dates and location for BASL2022 shortly.









The British Association for the Study of the Liver is a multi-disciplinary society with around 900 members composed of interested individuals from clinical medicine, clinical and basic research and allied professions.

Read More

British Liver Nurses' Association is a professional nursing organisation aiming to develop knowledge and understanding of liver disease, in order to improve the quality of patient care.

Read More

The British Viral Hepatitis Group aims to improve the management and study of patients with chronic viral liver disease, bringing together UK hepatologists, gastroenterologists, infectious disease physicians, virologists and interested epidemiologists.

Read More

The BLTG (British Liver Transplant Group) was launched in 2014 to represent the professional interests of liver transplantation in the UK and promote strategic and academic development. The BLTG will foster close relationships with BTS (British Transplant Society) and LICAGE (Liver Intensive Care Group of Europe) and will build on the role of the UK and Ireland Annual Meeting by delivering structure and authority to the group.

Read More

Is a professional pharmacy organisation aiming to develop knowledge and understanding of liver disorders including viral hepatitis, in order to improve the quality of patient care, through medicines optimisation, collaborative and multi-disciplinary working and promoting patient-focused research.

Read More

HCC UK is a multi-disciplinary organisation aiming to promote collaboration in research, education and clinical service development for primary liver cancer. We bring together leading oncologists, liver surgeons, hepatologists, basic scientists, radiologists, pathologists and specialist nurses to lead improvement in the quality of patient care.

Read More


IQILS Accreditation Programme Update

News Type: BASL News

2021 was a year of significant progress for the IQILS accreditation programme. The programme is in its strongest position since it launched back in 2021. The first few onsite accreditation assessments were conducted in the latter stages of 2021. We would like to congratulate the services at University Hospital Southampton NHS Foundation Trust and North Bristol NHS Trust on being awarded accreditation. Dr James Ferguson, the IQILS clinical lead has commented on the outstanding level of care, compassion and innovation these services have demonstrated. Several assessments will be taking place in the early part of 2022. Currently the programme has 61 registered services, 2 accredited services and 12 services are currently signed off for the level 1 standards.

Introduction to IQILS accreditation programme – Tuesday 15 February 2022, 09:30 – 11:00
If you would like to learn more about the IQILS programme.  A virtual introduction to IQILS accreditation session is being ran. This session is designed for services not yet registered to the programme and are interested in finding out more. During the session delegates will learn about:
• What is accreditation and how it can add value to your service
• The process and logistics involved in accreditation
• The overall benefits of registering

The session will be led by the Dr James Ferguson, IQILS clinical lead and Dr Andrew Yeoman, the QA lead of the IQILS programme. The session will take place via MS teams. Once you have registered an invite will be sent to all delegates with the dial in details. Registration for services is open.

Services registered to the programme receive access to the following benefits:
• The full accreditation standards
• Access to the IQILS website and self-assessment webtool
• Regular virtual training session on the accreditation process and standards
• Online repository of best practice templates and documents
• Regular newsletters on the programme with updates
• Support from the IQILS office team

If your service is interested in registering, please visit the IQILS website to sign up; .

Accreditation helps services to:
• independently measure themselves against national standards
• reduce variation in quality standards of their services
• demonstrate dedication to improvement, patient safety and reducing risk
• raise their profile, which can often be used to leverage support in their organisation
• highlight good practice and get targeted advice on where to focus improvement efforts

Please contact the IQILS team at or 0203 3075 1508 if you would like to speak to the team about the programme. IQILS has recently joined twitter, follow us @IQILS_Liver .

(Added 5/01/2022)

Joint BASL and BSG Statement: Information regarding new monoclonal antibody drugs against Covid-19

News Type: BASL News

With the rapid rise in cases of the Omicron variant of COVID-19 in the UK the NHS potentially faces another surge in hospital admissions and we are all facing familiar uncertainty and drawing on our resilience mechanisms again. The uncertainty is compounded by not yet knowing the severity or otherwise compared to the Delta variant, the moderating effect of vaccination and whether enough of the population are either vaccinated or boosted to exert this effect, and how the new monoclonal antibody drugs for symptomatic mild to moderate disease in the community will impact on admissions. Below is a summary from the relevant policies, with links, for your information.

These new monocolonals now have conditional marketing authorisation for use in non-hospitalised patients in the UK (read the website alert by clicking > here ). 

  • Sotrovimab is given by single intravenous infusion and is reported to reduce the relative risk of hospitalisation or death by 85%.
  • Molnupiravir is given orally by capsules for 5 days and is reported to reduce the relative risk of hospitalisation or death by 30%.

Patients must meet all of the eligibility criteria and none of the exclusion criteria. Prehospitalised patients are eligible for treatment if:
• SARS-CoV-2 infection is confirmed by polymerase chain reaction (PCR) testing within the last 5 days
• Onset of symptoms of COVID-193 4 within the last 5 days
• A member of a ‘highest’ risk group (as defined in Appendix 1).

Symptoms listed are: feverish, chills, sore throat, cough, shortness of breath or difficulty breathing, nausea, vomiting, diarrhoea, headache, red or watery eyes, body aches, loss of taste or smell, fatigue, loss of appetite, confusion, dizziness, pressure or tight chest, chest pain, stomach ache, rash, sneezing, sputum or phlegm, runny nose.

Appendix 1 includes liver disease in the following categories:
• Patients with cirrhosis Child’s-Pugh class B and C (decompensated liver disease).
• Patients with a liver transplant
• Liver patients on immune suppressive therapy (including patients with and without liver cirrhosis)
• Patients with cirrhosis Child’s-Pugh class A who are not on immune suppressive therapy (compensated liver disease)

Patients will be anxious, and as clinicians we may be contacted for advice. How the delivery of these drugs is to be organised is being worked out at local operational levels. Members are advised to make enquiries within their Trusts for local arrangements. The Liverpool COVID-19 interactions checker is a useful resource (click > here ). We checked these drugs against the more commonly used immunosuppressants and, for those not familiar with this tool, it is easy to use (no expected interactions for tacrolimus, ciclosprin, azathioprine, mycophenolate, prednisolone).

Members will no doubt be aware that casirivumab and imdevimab (Ronapreve®) has authorisation in hospitalised patients admitted with acute COVID-19. This seems to be less effective in patients with the Omicron variant. Thus where Omicron accounts for more than 50% of the local hospital prevalence, Ronapreve is only recommended where genotyping results are available and confirm infection with a non-Omicron variant. Where genotyping is not available or genotyping confirms infection with the Omicron variant, the December 2021 rapid policy statement advises nMABs can only be offered as part of a formal trial.

Nosocomial acquisition is a bit different. Ronapreve can be used in non-Omicron cases where known, meeting high risk criteria and Sotrovimab has also now been authorised for hospitalised patients who acquire Omicron variant COVID-19 during their hospital stay and meet high risk criteria - for our patients with liver disease, these are the same as those listed above. (read the website alert by clicking > here ). 

Again, members are advised to check their local Trust policies, but nosocomial acquisition of COVID-19 in patients with liver disease may well meet criteria for the use of these drugs so we thought we would draw your attention to this.

Hepatologists and gastroenterologists have faced very challenging changes to practice over the last two years and rising numbers of patients with liver disease. We know the changing Covid-19 landscape continues to bring new challenges. We hope you all stay safe and well during this period.

Rebecca Jones, President BASL
John Dillon, Vice President Hepatology, BSG

Download Joint BASL_BSG message re monoclonal antibody drugs vs COVID-19.pdf

(Added December 20th 2021)

Draft Clinical recommendations for pre-treatment assessment of people preparing to initiate therapy for chronic hepatitis C infection

News Type: BASL News

Dear BASL Members

Get Involved!

You are invited to send comments on the draft Clinical recommendations for pre-treatment assessment of people preparing to initiate therapy for chronic hepatitis C infection (link below) to Professor Graham Foster who has been coordinating this for NHS-E specialised commissioning.

Download Draft Clinical recommendations - therapy for chronic hepatitis C infection.pdf

Please contact Professor Foster directly by email by January 4th 2022.


News Type: BASL News

The Guts UK/Dr Falk awards recognise the achievements of those who bring new knowledge and insight to the field of gastroenterology, pancreatology and hepatology. These awards are an opportunity to achieve national recognition as well as the financial support for career progression.

Awards available:

  • A £1,000 prize for the best essay on gastroenterology or hepatology research personally undertaken by medical students who were on an intercalated BSc/MRes/MSc/MPH/MBPhD* course during the previous academic year (2020-21).
  • Four £1,500 prizes for medical students taking full-time science degrees (BSc/MRes/MSc/MPH/MBPhD*) focusing on gastrointestinal or liver-related disease in the current academic year (2021-22).
  • Two £2,500 awards for F1/F2 doctors to facilitate prospective research in an area relevant to gastroenterology or hepatology.
  • A £1,000 award for primary and secondary care gastrointestinal/liver nurses for initiatives that have improved patient care. (Nominate your colleague today for this award).
  • A £1,000 award for dietitians working in gastroenterology or hepatology for initiatives that have improved patient care.
  • Up to £10,000 is available for UK-based gastroenterology/hepatology SpR trainees who would like to conduct an audit or quality improvement project in any area of gastroenterology, liver disease or nutrition.

Applications will close at 17:00 on 28th February 2022

For further information and to apply: 

* PhD students should note that they may apply for the medical student prize only once during their three-year studentship and that they may apply for the essay prize when their PhD has been completed.

Foundation for Liver Research - Small Grants Scheme

News Type: BASL News

First Call for Applications

The Foundation for Liver Research has set up a new Small Grants Scheme in memory of the late Professor Roger Williams CBE (1931-2020). This scheme is open to any applicant in the UK.

Outline of the Small Grants Scheme

An Application form can be downloaded from the Foundation for Liver Research website > here

The closing date for the first Call is 1st March 2022.

For details of eligibility and the application process, contact Natalie Day, Chief Executive of the Foundation for Liver Research .


03/02/22 - 04/02/22

RCPE Hybrid* Course: 25th Advanced Gastroenterology & Hepatology Course
News Type: Other Events

Audience: This well-established, two-day course attracts trainees and consultants from across the UK and Globally.

Remit: The course will provide an update on the latest evidence base for the management and treatment of gastrointestinal and liver conditions presented by our expert speakers over the course of the two days including: Cytosponge in the diagnosis of oesophagogastric cancer// What is new in the management // The medical management of Crohn’s disease in 2022 – state of the art// Primary biliary cholangitis// Alcoholic liver disease.

Register: You can register per day for online delivery. *We hope to be able to have some in-person attendance which we will confirm to all registered delegates 4-6 weeks prior to course.

For full programme, fees and to book online: 



BASL Virtual School of Hepatology - February 2022 Session 1: ACLF - REGISTRATION NOW OPEN
News Type: BASL Events


Are you a budding Hepatologist? Do you want to improve your Hepatology knowledge to help with core and higher Hepatology curriculum sign off? Have you got Hepatology questions but not had the opportunity to ask them?

If yes then please join us for the BASL Virtual School of Hepatology Webinar Series 2022.

Following the success of the series in 2021 we are running a series of bi-monthly webinars this year on a Wednesday evening, with a face to face meeting being planned for the Summer.

We are delighed to announce our first session and speaker.

Session 1: "ACLF"
Speaker: Professor Rajiv Jalan - Royal Free Hospital London
Date: Wednesday 9th February
UK Time: 19:00 – 20:00

The BASL Virtual School of Hepatology Sessions offer an excellent platform for trainees interested in hepatology, with talks delivered by UK Hepatologists, followed by a Q&A session.

Preview the series programme here>  Download BASL Virtual School of Hepatology Webinar Prog 2022v1.pdf

NB: Programme subject to change

FREE to attend for BASL Members.

Not a member of BASL, then why not join by clicking > here.

REGISTER - through Zoom by clicking here.

Remember to read the BASL Events Data Protection Disclaimer below before registering:

Download  Download BASL Events Data Protection Disclaimer_2021.pdf

Please contact should you have any questions.


AASLD Hepatotoxicity SIG Seminar Series - February
News Type: Other Events

Time: 11:00am – 12:00pm EST / 15:00PM UK

A series of AASLD Hepatotoxicity SIG Seminars that will take place on the second Thursday of each month except for July, August and November (the Liver Meeting) through 2021 & 2022.

Title: “RECAM, An evidence-based update of the RUCAM based on DILIN and Spanish Registry data”
Presenter: Dr. Paul “Skip” Hayashi. DILI Team Lead, Division of Hepatology & Nutrition, Office of New Drugs Food and Drug Administration

Registration Link: 


16/03/22 - 18/03/22

Royal Free Sheila Sherlock Hepatology Postgraduate Course 2022
News Type: BASL Endorsed Events

The Royal Free Sheila Sherlock Hepatology Postgraduate course has developed an excellent reputation for its clinically relevant, interactive and curriculum-focussed content, designed for both gastroenterology and acute medicine trainees and consultants seeking an update that is tailored to everyday practice.

The course aim is to equip clinicians with the knowledge and skills to expertly manage patients with liver disease. The programme has been re-vamped for 2022, with sessions covering hepatology in the clinic, acute medical take, ITU and liver transplant settings. This is the 8th year that the course has been run, with consistently excellent delegate feedback.

This year the course will be held virtually, with live-streamed speakers and plenty of opportunities for audience interaction and questions.

Register through the ILDH UCL webpage .

The course programme can be viewed > here


BASL Introduction to Hepatology Day
News Type: BASL Events

The BASL Introduction to Hepatology Day that was being planned for March has been moved to Saturday 7th May 2022 and will be held at a venue in Birmingham. 

This one day event will be FREE to attend for BASL Trainee Members (a deposit will be taken at the time of booking). .

The meeting will be aimed at Junior Gastroenterology trainees or those considering applying for Gastroenterology to ensure the fundamentals of Hepatology are taught well aiming to cover some of the core Hepatology curriculum and for those considering pursuing a career in Hepatology who want advice.

A programme is currently being worked on and more details will follow once available.

Quick Links

Basl on Twitter